Linda C. Burkly, Ph.D.

Linda C. Burkly, Ph.D.

Executive Vice President and Chief Scientific OfficeratEditas Medicine· In proxies 2023–2025

Pay in FY2025Editas Medicine stock +61.4% the same year

Linda C. Burkly, Ph.D. was paid $1.2M in FY2025 (Dec). Editas Medicine stock rose 61.4% that year.

Pay$100 in the stock at the end of FY22 → $184
Pay is from the Summary Compensation Table of each Editas Medicine proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Editas MedicinePublic company · 3 yr
    • Executive Vice President and Chief Scientific Officer2023 – Present · 3 yrStock in role -65%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?